HYPOTHESIS

HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?

J H Ringrose

Abstract
Most autoimmune diseases are associated with certain HLA types. Therefore, spondyloarthropathies (SpA) strongly associated with HLA-B27, are also often classified as autoimmune diseases. This study questions whether SpA indeed fulfils the criteria of an autoimmune disease. The Medline database was searched for all reports between 1966 and April 1998 on the presence of autoimmune reactivity in SpA patients. This search yielded 45 articles on this subject. Only eight articles study T cell reactivity. Twelve reports were found on the assessment of antibodies crossreacting between bacteria and HLA-B27. In the 45 studies demonstrating autoimmune reactions in SpA patients proper controls matched for HLA-B27, sex and age were nearly always lacking. Therefore, it is concluded that the frequency of increased autoreactivity in sera from patients and controls is not significantly different, and that this lack of autoreactivity does not justify classification of SpA as an autoimmune disease. As crossreactive antibodies against bacteria and HLA-B27 were equally present in sera from patients and controls, the pathogenetic significance of molecular mimicry between various bacteria and HLA-B27 is questionable. Furthermore, the regions of the B27 molecule that are supposed to be crossreactive with bacteria, differ in one or more amino acids among the distinct B27 subtypes. Although these differences strongly influence the binding of antibodies to the B27 molecule, there was no relation between the degree of crossreactivity of certain subtypes and the association of these subtypes with SpA. In conclusion, there is no evident proof that SpA is an autoimmune disease attributable to crossreactivity between bacteria and HLA-B27.


The spondyloarthropathies (SpA) are a group of diseases including ankylosing spondylitis (AS), reactive arthritis (ReA), and Reiter’s syndrome (RS). One third of the HLA-B27 positive AS patients has also acute anterior uveitis (AAU), whereas more than half of the HLA-B27 positive patients with AAU fulfils the criteria for SpA. A remarkable high association between AS, ReA, RS and AAU and the expression of the MHC class-I molecule HLA-B27 is reported. The assumption is often made that B27 associated diseases are autoimmune diseases (AID). Because a number of bacterial species have been associated with the initiation of ReA, and because a high prevalence of Klebsiella pneumonia and of antibodies to Klebsiella in AS patients has been reported, it has been suggested that bacteria play a part in the pathogenesis of B27 associated SpA. The term “molecular mimicry”, introduced in 1964, describes the resemblance of antigenic epitopes of microbial constituents and autologous material. Molecular mimicry between viral proteins and host cell proteins has been suggested to be one of the causes of AID. Therefore, the hypothesis has also been made that molecular mimicry between bacteria and HLA-B27 plays a pathogenetic part in HLA-B27 associated SpA.

Various theories are proposed to explain the association of SpA with B27. Several of them involve some form of molecular mimicry. In these theories B27 functions as a T cell restriction element, as an antigen, or both as an antigen and a T cell restriction element: (1) B27 presents a bacterial derived peptide to B27 restricted CD8 positive CTL crossreacting with self peptides presented by B27, (2) B27 molecules would present a peptide derived from B27 itself with sequence similarity with bacteria. (3) Peptides derived from the B27 molecule would be presented by MHC class II molecules to CD4 positive T cells that previously have been activated by bacterial antigens. (4) Antibodies induced by bacteria may crossreact with B27 molecules, thereby initiating an autoimmune response.

In several studies data had been obtained that supported the idea that possible crossreactions between bacteria and the B27 molecule may be responsible for the induction of autoimmune reactions directed against the B27 molecule. Using polyclonal anti-sera raised in various animals, many groups studied a...
possible crossreactivity between several bacterial species (Klebsiella pneumoniae, Enterobacter aerogenes, Shigella sonnei, Yersinia enterocolitica, Chlamydia trachomatis) and HLA-B27. Possibly because of non-specific binding in the serological methods used, such crossreactions were not observed by all research groups. Using more specific monoclonal antibodies reactive with B27 or bacteria, it was demonstrated that crossreactivity between Yersinia enterocolitica, Shigella sonnei, Shigella flexneri, Salmonella typhimurium, Klebsiella pneumoniae and HLA-B27 may occur. Using polyclonal anti-Klebsiella sera some evidence was obtained that suggested the existence of a B27 associated crossreactive epitope that was specifically present on lymphocytes of AS patients, and only on B27 positive lymphocytes of healthy persons after incubation of these lymphocytes with a Klebsiella culture-filtrate derived factor. Later, serological recognition of B27 was shown to be influenced by oxidation of the free sulphhydryl group of the cysteine at position 67 of the B27 molecule, something that can be achieved by interaction of B27 with homocysteine (a product produced by bacteria). Thus, certain factors were shown to be able to modify the serological properties of B27, which in people might lead to recognition of B27 as non-self. All these findings support the hypothesis that B27 associated SpA may be an AID, and that they may be caused by molecular mimicry between B27 and bacterial components. It is, however, not at all clear whether the published data validate the classification of SpA as an AID attributable to molecular mimicry between HLA-B27 and bacteria.

The criteria for AID are not clearly defined. This has resulted in a tendency to consider some diseases of unknown origin as AID, even though the role of autoimmune phenomena in these diseases in humans are not clear at all. The term “autoimmunity” was first introduced at the beginning of this century by Ehrlich, who formulated the concept of “Honor autoxicus”. His concept is often misunderstood as meaning that autoantibodies may not be formed. The true meaning however is that autoantibodies may be formed and can be found, but that in healthy people mechanisms exist that somehow prevent their action and thus inhibit the development of AID. Sera from normal animals and humans of any age contain a wide variety of autoantibodies, including antibodies reactive with molecules involved in the immune system. Thus, the presence of autoantibodies in people with particular diseases, does not indicate that such antibodies play a part in the pathogenesis of these diseases, or that these diseases can be regarded as AID. The presence of autoantibodies only points to autoimmune reactivity and not necessarily to autoimmune disease. The induction of autoantibodies might be secondary to disease and have been induced for example by tissue damage because of non-autoimmune mechanisms.

Nevertheless, autoantibodies in high titres can be useful diagnostic markers for certain diseases. Their presence, however, does not prove that autoimmune reactions really are the cause of diseases. Direct evidence as defined by Rose is “the demonstration that a self-reactive antibody is the immediate cause of injury or dysfunction”. This has been demonstrated for the autoimmune forms of haemolytic anaemia, thrombocytopenia, leucopenia and for diseases where antibodies to receptors are involved, for example, Graves’ hyperthyroidism and myasthenia gravis. According to Rose, indirect evidence for a pathogenetic role of autoantibodies requires the identification and isolation of the appropriate autoantigen. Subsequent immunisation of suitable animals with this antigen should reproduce the lesions of the disease. According to Rose, most of the so called autoimmune diseases are, however, only defined on the basis of circumstantial evidence, including the presence of other autoimmune disorders in the same person or in the family, associations with particular HLA haplotypes and a markedly skewed T cell receptor V-gene use. Feltkamp, considering that all autoimmune diseases are characterised by autoimmune reactions, favours a more practical definition of an autoimmune disease: “An autoimmune disease is characterised by a significantly increased frequency of autoantibodies and autoreactive T cells compared to healthy local controls”. Because for several human autoimmune diseases the preponderance of women is striking and sex hormones can modify immune responses, and as age and the hygienic quality of life of a population influence the chance for developing various autoimmune diseases, it is important to include local controls that are matched for sex and age in studies assessing AID.

Considering the above information the following definition can be used. “Autoimmune diseases are diseases in which immune reactivity directed against autologous antigens is significantly increased when compared with normal individuals, whilst this reactivity is the primary cause of tissue or cell destruction”. Regarding SpA, the aforementioned definitions mean that HLA-B27 associated SpA only can be designated as AID if the presence and nature of autoimmune reactions can be demonstrated. Thus, in SpA patients autoreactivity should be at least more often present in higher levels than in well defined controls, who should have to be matched for sex and for age. Assessment of autoantibodies and autoreactive T cells in cases and controls should have to be performed with the same techniques with the same sensitivity. As the MHC background has been shown to influence the susceptibility to certain autoimmune diseases, and as in B27 transgenic mice antibodies and T cell responses to B27 could not be induced by immunisation with B27 derived peptides compared with non-transgenic mice, controls should also have to be matched for HLA-B27. If sera or T cells are used to study whether they react both with HLA-B27 and bacteria, additional experiments have to be performed to confirm that crossreactive antibodies or T cells are present in the sera, to exclude the possibility that the crossreactivity was...
attributable to coexistent antibodies and T cells with different specificities for bacteria and B27. In this study data from literature were collected to answer the question whether SpA can be designated as an AID, and whether crossreactivity between HLA-B27 and bacteria plays a part in the pathogenesis of B27 associated SpA.

<table>
<thead>
<tr>
<th>Immunoreaction</th>
<th>Reference</th>
<th>Year</th>
<th>Humoral resp. Ig/A/G/M</th>
<th>Cellular assays</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-69 kD protein</td>
<td>62</td>
<td>1991</td>
<td>Ig</td>
<td></td>
</tr>
<tr>
<td>Anti-antineur. ligament</td>
<td>90</td>
<td>1983</td>
<td>G</td>
<td>Stim.</td>
</tr>
<tr>
<td>Anti-articular cartilage</td>
<td>91</td>
<td>1976</td>
<td>Ig</td>
<td>MI</td>
</tr>
<tr>
<td>Anti-C1q</td>
<td>92</td>
<td>1992</td>
<td>G, A</td>
<td></td>
</tr>
<tr>
<td>Anti-cardiolipin</td>
<td>63</td>
<td>1987</td>
<td>G+M</td>
<td></td>
</tr>
<tr>
<td>Anti-cartil. link protein</td>
<td>93</td>
<td>1988</td>
<td>G</td>
<td></td>
</tr>
<tr>
<td>Anti-collagen n1; n2; n3; n4</td>
<td>94</td>
<td>1980</td>
<td>G</td>
<td></td>
</tr>
<tr>
<td>d1</td>
<td>95</td>
<td>1980</td>
<td>G</td>
<td></td>
</tr>
<tr>
<td>n1; n2</td>
<td>96</td>
<td>1980</td>
<td>G</td>
<td></td>
</tr>
<tr>
<td>n2</td>
<td>97</td>
<td>1981</td>
<td>G, M</td>
<td></td>
</tr>
<tr>
<td>d2; n2</td>
<td>98</td>
<td>1984</td>
<td>G</td>
<td></td>
</tr>
<tr>
<td>C2 peptides</td>
<td>99</td>
<td>1994</td>
<td>CTL cloning</td>
<td></td>
</tr>
<tr>
<td>n2</td>
<td>61</td>
<td>1997</td>
<td>G, A, M</td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>60</td>
<td>1997</td>
<td>A</td>
<td></td>
</tr>
<tr>
<td>Anti-DNA ss; ds</td>
<td>63</td>
<td>1987</td>
<td>G, M</td>
<td></td>
</tr>
<tr>
<td></td>
<td>69</td>
<td>1992</td>
<td>G, M &gt;1:10</td>
<td></td>
</tr>
<tr>
<td>Anti-HSP60</td>
<td>56</td>
<td>1996</td>
<td>G Mean Abs</td>
<td></td>
</tr>
<tr>
<td>Anti-intervertebral disc</td>
<td>90</td>
<td>1983</td>
<td>G</td>
<td></td>
</tr>
<tr>
<td>Anti-keratin</td>
<td>101</td>
<td>1995</td>
<td>A, G</td>
<td></td>
</tr>
<tr>
<td>ANCA</td>
<td>101</td>
<td>1995</td>
<td>A, A</td>
<td></td>
</tr>
<tr>
<td>ANF Liver</td>
<td>65</td>
<td>1967</td>
<td>Ig &gt;1:16</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>66</td>
<td>1967</td>
<td>Ig</td>
<td></td>
</tr>
<tr>
<td>Leucocytes</td>
<td>67</td>
<td>1967</td>
<td>Ig &gt;1:16</td>
<td></td>
</tr>
<tr>
<td>Granulocytes; liver</td>
<td>58</td>
<td>1977</td>
<td>Ig</td>
<td></td>
</tr>
<tr>
<td>Leucocytes</td>
<td>68</td>
<td>1979</td>
<td>Ig &gt;1:40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>59</td>
<td>1981</td>
<td>Ig &gt;1:20</td>
<td></td>
</tr>
<tr>
<td></td>
<td>69</td>
<td>1992</td>
<td>Ig &gt;1:40</td>
<td></td>
</tr>
<tr>
<td>HEP-2</td>
<td>101</td>
<td>1995</td>
<td>G</td>
<td></td>
</tr>
<tr>
<td></td>
<td>102</td>
<td>1993</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APF</td>
<td>103</td>
<td>1995</td>
<td>Ig &gt;1:80 1:100</td>
<td></td>
</tr>
<tr>
<td></td>
<td>104</td>
<td>1979</td>
<td>Ig &gt;1:80</td>
<td></td>
</tr>
<tr>
<td></td>
<td>105</td>
<td>1990</td>
<td>Ig &gt;1:80</td>
<td></td>
</tr>
<tr>
<td>Anti-sacroiliac joint cart.</td>
<td>90</td>
<td>1983</td>
<td>G</td>
<td>Stim.</td>
</tr>
<tr>
<td>Anti-salivary duct</td>
<td>106</td>
<td>1967</td>
<td>G</td>
<td></td>
</tr>
<tr>
<td>Anti-synovial membrane</td>
<td>91</td>
<td>1976</td>
<td>G</td>
<td>MI</td>
</tr>
<tr>
<td>Anti-thyroglobulin</td>
<td>107</td>
<td>1979</td>
<td>G</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Immunoreaction</th>
<th>Reference</th>
<th>Osteoarthritis Degenerative joint disease Gout</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-69 kD protein</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Anti-antineur. ligament</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>Anti-articular cartilage</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>Anti-C1q</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>Anti-cardiolipin</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td></td>
<td>64</td>
<td></td>
</tr>
<tr>
<td></td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>Anti-cartil. link protein</td>
<td>93</td>
<td>7/29</td>
</tr>
<tr>
<td>Anti-collagen n1; n2; n3; n4</td>
<td>94</td>
<td>0;0;0;3/10</td>
</tr>
<tr>
<td>d1</td>
<td>95</td>
<td>3/15</td>
</tr>
<tr>
<td>n1; n2</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>n2</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>d2; n2</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>C2 peptides</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>n2</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Anti-DNA ss; ds</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td></td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>Anti-HSP60</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>Anti-intervertebral disc</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>Anti-keratin</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>ANCA</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>ANF Liver</td>
<td>65</td>
<td>0/8</td>
</tr>
<tr>
<td>Liver</td>
<td>66</td>
<td>0/8</td>
</tr>
<tr>
<td>Leucocytes</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>Granulocytes; liver</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Leucocytes</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td></td>
<td>59</td>
<td></td>
</tr>
<tr>
<td></td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>HEP-2</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td></td>
<td>102</td>
<td></td>
</tr>
<tr>
<td>APF</td>
<td>103</td>
<td></td>
</tr>
<tr>
<td></td>
<td>104</td>
<td></td>
</tr>
<tr>
<td></td>
<td>105</td>
<td></td>
</tr>
</tbody>
</table>

↑ = Increased mean absorbance in ELISA. Bold type* = significant (p<0.05) if compared with healthy controls. + = Significantly increased frequency of autoimmune reactions among B27 associated SpA compared with controls (healthy or suffering from other rheumatic disorders). A = IgA, Abs = absorbance in ELISA assay, Arthr = arthritis, Cart = cartilage, Deg = degenerative, ds = double stranded, G = IgG, Ig = immunoglobulin, m = mean, M = IgM, MI = migration inhibition, NS = not significant, resp = response, SLB = systemic lupus erythematosus, SF = synovial fluid, ss = single stranded, Stim = lymphocyte stimulation.
Table 1 continued

<table>
<thead>
<tr>
<th>Ankylosing spondylitis</th>
<th>Reactive arthritis</th>
<th>Reiter syndrome</th>
<th>SpA</th>
<th>RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>?/138</td>
<td></td>
<td></td>
<td></td>
<td>?/29</td>
</tr>
<tr>
<td>0/8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6/6/20 Mean: 0.87±0.95* G: 5/18 M: 1/18 1/7</td>
<td>1/9</td>
<td>2/0/2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean: 0.11* 0.07* 0.14 Mean 7* G: 5/0/28 M: 1/12/28 0/5</td>
<td>1.6* n=9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0/8</td>
<td></td>
<td></td>
<td></td>
<td>0.87 n=9</td>
</tr>
<tr>
<td>9,15,13 n=20 NS G:12/22 A:8/22</td>
<td>0/2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0/27</td>
<td></td>
<td></td>
<td></td>
<td>0/27</td>
</tr>
<tr>
<td>0/18 (AS+PsoA) 7/121* 5/28 M: 6/36 7/11* 0/3</td>
<td>0/22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7/84</td>
<td>2/6/80</td>
<td>2/36 3/62 2/26 0/8</td>
<td>0/1</td>
<td></td>
</tr>
<tr>
<td>Ig: 0/15 MI&gt;Contr.* 1/1 SF</td>
<td></td>
<td></td>
<td></td>
<td>0/15 MI&gt;Contr.*</td>
</tr>
<tr>
<td>SLE</td>
<td>Psoriatic arthritis</td>
<td>Normal controls</td>
<td>Sex/HLA matches</td>
<td>Conclusions</td>
</tr>
<tr>
<td>G:30/88 A:0/88</td>
<td>3/80 2/80 0/10</td>
<td>2/19 0/152</td>
<td>G:2/40 M:3/40 A:0/40 0/0;0/1/10</td>
<td>Sex + age +</td>
</tr>
<tr>
<td>4/9</td>
<td>7/13 2/1/3</td>
<td>0/14 n=40</td>
<td>G:0/14 M: 1/14 n=15</td>
<td>No</td>
</tr>
<tr>
<td>2/0/8</td>
<td>2/1/50</td>
<td>0/4</td>
<td>m: 0.09 0.06 0.12</td>
<td>No +</td>
</tr>
<tr>
<td>1.0 n=12</td>
<td>0.96 n=9</td>
<td>0.16</td>
<td>0.09 0.16 n=58</td>
<td>No +</td>
</tr>
<tr>
<td>24*,11,12 n=42</td>
<td>5/34</td>
<td>0/12</td>
<td>7/112</td>
<td>Sex + age +</td>
</tr>
<tr>
<td>4/11</td>
<td>0/0</td>
<td>0/7</td>
<td>7/52, 1/32</td>
<td>No</td>
</tr>
<tr>
<td>5/34</td>
<td>3/108</td>
<td>n=8</td>
<td>0/9</td>
<td>No</td>
</tr>
</tbody>
</table>

**Source of data**

The Medline database was searched with Ovid software for English language literature that appeared between 1966 and April 1998 using the following subject headings: spondylitis, ankylosing; arthritis, reactive; Reiter’s syndrome. This resulted in 5082 references. This search was further limited to those with the
following text words present in the title, abstract, or the subject headings: autoantigen or autoantigens; autoantibody or autoantibodies; autoreactive or autoimmune; serology or culture; antigen or antigens; antibody or antibodies; Salmonella or Yersinia or Chlamydia or Klebsiella or Shigella or Campylobacter; infection or infections; T cells or T lymphocytes; bacteria or bacterial. This resulted in 2516 references. All titles of these 2516 reports were used to exclude those reports that did not cover the subject of our study. In total, 1515 references were not appropriate. Usually, the above searched text words were only mentioned in other contexts. The remaining 1001 references were imported in a database using Reference Manager software. The abstracts of these 1001 articles were read to find those studies in which the presence and nature of autoimmune reactions in B27 associated SpA was studied. Again, the fall out usually consisted of reports in which the above searched text words were only present in other contexts. Subsequently, reviews and case reports were excluded. Finally, only 45 articles reported on studies that were relevant for the question whether B27 associated SpA are AID, and 12 articles reported on studies that were relevant for the question whether SpA is caused by molecular mimicry between bacteria and B27.

**Results**

The results are presented in the following three paragraphs: Autoreactivity against antigens other than HLA-B27; Autoreactivity against HLA-B27; Crossreactivity between bacteria and HLA-B27.

**AUTOREACTIVITY AGAINST VARIOUS ANTIGENS OTHER THAN HLA-B27**

The 32 articles reporting on the measurement of autoimmune responses in B27 associated SpA, encompassed 30 studies on AS, six on RS and four on ReA. Of these 32 reports, 27 reported on autoantibody responses and only six on T cell autoreactivity. The antibodies studied, cover a wide range of different autoantigens including phospholipids, cartilage link protein, collagen like C1q, keratin, thyroglobulin, heat shock protein, perinuclear factor, nuclear antigens and neutrophil cytoplasmic antigens (ANCA).

In six studies, marked with "++" in the column "conclusion" in table 1, the frequency or level of autoimmune reactions were significantly increased among B27 associated SpA patients compared with controls (healthy or suffering from other rheumatic disorders). Immune reaction against a 36 kDa protein from Drosophila melanogaster was found to be increased in B27 positive and negative AS patients when compared with RA and healthy controls who were not matched for HLA or sex.65 When antibodies that reacted with the 36 kDa antigen were eluted from the 36 kDa protein after incubation with pooled AS patient sera, it was found that these antibodies reacted with a 69 kDa protein isolated from human lymphocytes or HeLa cells. Also pooled sera from AS patients reacted with this 69 kDa protein. However, because in these studies pooled sera were used, it is not clear how many individual patients that recognise the 36 kDa and 69 kDa Drosophila protein also recognise the 69 kDa human protein, and how many patient and control sera react with this 69 kDa protein.

Levels of antibodies to HSP60, present in sera from RA, SLE, Reiter’s patients and healthy controls, were reported to be slightly increased in sera from Reiter’s patients in one study. The controls were not matched for HLA, sex or age.

One study reported a higher incidence of IgG anti-cardiolipin in AS patients compared with normal controls matched for age and sex, but not for HLA. However, in two other studies in which no matches for HLA, sex and age were performed, the frequency of raised levels of anti-cardiolipin antibodies in sera from AS patients was not different compared with rheumatoid arthritis (RA) patients or healthy controls.

In only one of seven studies in which the presence of antibodies against collagen was analysed, AS patients had slightly increased levels of anti-collagen antibodies. Controls were not matched for HLA, sex or age.

In three studies it was reported that no antinuclear antibodies (ANA) in AS patients and controls at a dilution of more than 1:16 were found, whereas 15% to 30% of RA patients were positive. At a dilution of 1:16 approximately 60% of 18 AS patients and 77% of 144 non-rheumatic disease controls were positive for ANAs, while 90% of 184 RA patients were positive. No HLA, sex, or age matches were performed. Vasey and Kinsella, testing for leucocyte reactive (LR) ANAs by measuring reactivity with granulocyte nuclei, found that 60% of 125 AS and 47% of 124 RA patients was positive. These percentages are significantly higher than for patients with inflammatory disorders (12% of 34 positive) and healthy controls (9% of 122 positive). Among 74 patients with miscellaneous disorders 40% was positive. Although no matches for HLA, sex, or age were used in this study, no correlation was found between the presence of B27 and LR-ANAs. The LR-ANAs in AS patients, although not granulocyte specific, were specific for leucocytes and did not react with other human or non-human substrates. This might explain the discrepancy with the negative results in the previous studies, in which liver tissue instead of granulocytes was used as substrate. LR-ANA positive sera from 50% of the RA patients and all SLE patients reacted also with adrenal and thyroid tissue as substrates.

Rosenberg et al. found that only 6% of 88 AS patients and 13% of 52 psoriatic arthritis (PsOA) patients had ANAs reactive with granulocytes, whereas all 25 psoriasis patients and 91 chest disease controls were negative. Measuring ANAs reactive with liver tissue they found that at serum dilutions of 1:40 17% of 36 AS and 3% of 32 PsOA patients were positive. These frequencies are rather low compared with other reports, except in the study of Vasey and Kinsella in which none of...
Table 2  Frequencies of the presence of anti-B27 antibodies in sera from SpA patients and controls

<table>
<thead>
<tr>
<th>B*2705 residues</th>
<th>Reference</th>
<th>AS patients</th>
<th>RS patients</th>
<th>Healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>B27</td>
<td>B27</td>
<td>B27</td>
</tr>
<tr>
<td>69–84</td>
<td>Schwimmbeck et al70–71</td>
<td>7/124*</td>
<td>1/34*</td>
<td>0/22</td>
</tr>
<tr>
<td>69–84</td>
<td>Tsuchiya et al72–73</td>
<td>14/50</td>
<td>14/60</td>
<td>1/5</td>
</tr>
<tr>
<td></td>
<td>et al67–83</td>
<td>2/26</td>
<td>0/6</td>
<td>0/6</td>
</tr>
<tr>
<td></td>
<td>Tani et al67–83</td>
<td>77% male</td>
<td>84% male</td>
<td>50% male</td>
</tr>
<tr>
<td></td>
<td>Fielder et al74–75</td>
<td>7/24*</td>
<td>18/34*</td>
<td>20</td>
</tr>
<tr>
<td>68–75</td>
<td>Ewing et al76</td>
<td>↑ Ig*</td>
<td>n=50</td>
<td>n=32</td>
</tr>
<tr>
<td>69–84</td>
<td>de Vries et al77</td>
<td>↑ Ig*</td>
<td>n=81</td>
<td>n=32</td>
</tr>
<tr>
<td>67–83</td>
<td>Tani et al78</td>
<td>↑ A*,G*,M*</td>
<td>90% male</td>
<td>50% male</td>
</tr>
<tr>
<td>67–83</td>
<td>Fielder et al79</td>
<td>↑ A,G*,M</td>
<td>n=97</td>
<td>n=50</td>
</tr>
</tbody>
</table>

† =Increased mean absorbance in ELISA. Bold type* = significant (p<0.05) if compared with healthy controls. A = IgA, G = IgG, M = IgM, n = number of subjects studied.

The sera from AS patients reacted with liver tissue. Rosenberg et al76 used fixed leucocytes as substrate, whereas Vasey and Kinsella77 used unfixed leucocytes. However, Rosenberg et al76 using fixed leucocytes similar to those used by Vasey and Kinsella, were still not able to confirm the findings of Vasey and Kinsella.78 In these studies no HLA, sex or age matches had been performed. In a later study, Kinsella et al again found a higher incidence of LR-ANA in AS patients than in normal controls (45% of 31 AS patients, 7% of 31 controls at 1:10 dilution, and 23% of 31 AS, 0% of 31 controls at 1:20 dilution).79 In this study, patients and controls were matched for sex and age (± 2 years), but HLA matches were not performed. All AS patients were B27 positive and almost all controls were B27 negative, but there was no concordance between LR-ANA and B27 positivity in North American natives. Wong et al70 testing only three patients with B27 positive AS and their family members for ANAs reactive with Hep-2 cells, found that at a dilution of 1:40, all persons had ANA reactivity within normal range.

**AUTOREACTIVITY AGAINST HLA-B27**

Schwimmbeck et al70–71 used peptides from residues 69–84 of HLA-B*2705, as substrate in an ELISA system to detect antibodies against B27. Eighteen of 34 (53%) B27 positive RS patients and 7 of 24 (29%) B27 positive AS patients tested at a dilution of 1:10 were positive. None of the 22 B27 positive healthy controls were positive. Thus, patients were shown to have higher titres of antibodies against B27 than controls who were matched for HLA, but not for sex or age (table 2).

Tani et al72 tested sera from Japanese patients at a dilution of 1:50 for antibodies to the 67–83 B*2705 peptide with an ELISA, and found that active AS patients had significantly higher antibody levels against the B*2705 peptide in all antibody subclasses, and that inactive AS patients had only raised IgG subclass antibody levels compared with healthy normals and RA patients. Antibody levels against a control peptide were not different in the different groups. All AS patients were B27 positive, but the controls were not matched for HLA, sex or age. Of the RA patients 90% were women, while 90% of the AS patients and 50% of the controls were men. Fielder et al73 using the same method and the same peptides, found that active AS patients had significantly higher IgG subclass antibody levels than RA patients and controls who were also not matched for HLA, sex or age. The levels of IgM and IgA subclasses were similar in patients and controls.

Tsuchiya et al74–75 used the same technique as Schwimmbeck with the 69–84 peptide from B*2705. Patients and controls from Tromso (Norway) were sex (only men were included) and age matched. The mean age of the patients was 38 years, ranging from 20 to 69, and of the controls 40 years, ranging from 21 to 62. Fourteen of 60 (23%) AS patients of whom 83% were B27 positive, one of eight (13%) RS patients of whom 63% were B27 positive, and one of 24 (5%) normal controls of whom 44% were B27 positive, had antibodies against the B27 peptide 69–84. The difference of the positive ratio between AS and controls was only significant when no HLA matches were performed. However, when the same studies were performed on patients from New Mexico, no significant differences were found between patients and controls who were not matched for age. In a study using the lymphocyte migration inhibition test for patients as well as for controls, no significant differences were found between the migration inhibition (MI) induced by a B27 peptide and the MI induced by a control peptide.74–75 When values of MI induced by the B27 peptide were compared with those induced by blank wells containing no peptides at all, it appeared that the proportion of normal controls responding to the B27 peptide was larger than that of patients, although the difference was not statistically significant (p>0.10). The results obtained by ELISA used in this study were corrected for non-specific serum binding. Schwimmbeck et al70–71 has not reported such correction. Women were excluded from the studies by Tsuchiya et al because they found increased titres against the B27 derived peptide were present in seven of 34 (21%) B27 negative female controls and also in two of nine (22%) B27 positive female controls who had previously been pregnant. Most of their female patients had been pregnant, and the titres in these patients were
similar to the titres in the B27 positive or B27 negative female controls with previous pregnancies. The group of female patients without previous pregnancies was too small to study. Cavender et al. found neither antibodies against B27 in any of six male AS or RS patients, nor in sex and age matched B27 negative controls. They used B27 positive lymphoblastoid cells as targets in a microlymphocytotoxicity assay.

Ewing et al. used a variety of synthetic peptides derived from HLA-B27 as substrates in ELISA systems. Analysing the specificity of a number of patient sera recognising peptides from B*2705, they found two different reactive sites in the B27 peptides. Using octamers they observed that reactivity to the sequence 72-QTDREDLR-79 was absent, and that reactivity was mainly present to two peptides, 68-KAKAQTDR-75 and 76-REDLRTL-83. At a dilution of 1:2000, sera from 50 B27 positive AS patients, and 22 B27 positive and 22 B27 negative healthy first degree relatives as controls were studied for antibodies to 68-KAKAQTDR-75. The mean absorbance values in the ELISA of the sera from the patients were significantly higher than the mean absorbance of either groups of control sera. However, this difference was mainly caused by three of the 50 patient sera, which showed extremely high reactivity against B27. No significant differences between the mean absorbance values of the B27 positive and B27 negative controls were found. No sex or age matches were performed.

De Vries et al. used the same technique and peptide substrate (69–84 B*2705 peptide) as Schwimmbeck et al. They studied 81 B27 positive AS patients, 38 B27 positive RS patients, and 32 B27 positive and 49 non-typed healthy controls. Like Tsuchiya et al. they could not reproduce the results reported by Schwimmbeck et al, although their first findings confirmed the results of Schwimmbeck et al. Sera from AS patients bound the B27 peptide significantly better than the control serum samples. However, differences were only significant if the results from all patients were compared with those from non-HLA typed controls. The results from B27 positive patients and the B27 positive controls were not significantly different. Patients with RS showed a higher, although not significantly, binding than non-HLA typed controls. Binding of sera from 32 B27 positive healthy controls was relatively high, but this was caused by nine serum samples of which seven were obtained from women of whom no data of possible previous pregnancies were available. Control experiments carried out with uncoated wells or wells coated with an irrelevant peptide, showed that there was a highly significant correlation between binding to both the B27 peptide and an irrelevant peptide, and even to uncoated wells. Apparently the degree of a-specific binding was high. All groups were matched for sex (79% men), but not for age.

Herrmann et al. studied proliferation of peripheral blood lymphocytes (PBL) using 13 short synthetic peptides of B27. The only conclusion that could be drawn from the results of this study was that B27 positive AS patients as well as B27 positive healthy controls recognise a peptide corresponding to residues 60–72 from B*2705. A peptide corresponding to residues 151–165 was recognised by almost all groups studied (B27 positive AS, B27 positive other SpA, B27 positive healthy, B27 negative healthy). These groups were only matched for B27 and not for sex or age.

All the above studies make use of short synthetic peptides. There are only very few reports studying the possible recognition of conformational epitopes on whole B27 molecules by antibodies or T cells.

Kellner et al. used flow microfluorometry analysis to measure antibodies reacting with B27 positive cells transfected with the Mycobacterium tuberculosis HSP60 gene. Sera of 11 B27 positive AS patients, 13 B27 positive RS patients, six B27 positive healthy persons and 12 non-HLA typed healthy controls were studied. No sex or age matches were performed. They found that the mean fluorescence intensities for the RS patient sera and for the AS patient sera were significantly higher than for either control group sera. Experiments were done that indicated that this was mediated by serum antibodies that were recognising HLA-B27 restricted epitopes with peptides derived from the Mycobacterium tuberculosis HSP60.

Gao et al. reported on cytotoxic T cell (CTL) recognition of homocysteine modified B27 molecules. CTL in PBL cultures of two of three B27 positive AS patients, one of one B27 positive ReA patient and none of two healthy controls of which one was B27 positive, specifically recognised homocysteine modified B27 molecules on autologous B cell lines. No sex or age matches were performed. HLA-A68 restricted homocysteine specific CTL (Hom-CTL) from a B27 negative patient also recognised Salmonella infected target cells, suggesting that also Salmonella infection can lead to the modification of HLA antigens that is recognised by Hom-CTL.

Herrmann et al. found in synovial fluid from four (one B27 negative, three B27 positive) of six SpA patients (four ReA, two AS) a significant frequency of autoreactive CTL. Also B27 restricted autoreactive CTL clones specific for an as yet unidentified peptide were isolated. No studies were done on synovial fluid from controls.

CROSSREACTIVITY BETWEEN BACTERIA AND HLA-B27

After the sequence of the B27 molecule had been unravelled, more precise data about possible crossreactive epitopes on B27 and bacteria could be obtained than from experiments with antisera raised in animals. Using DNA hybridisation techniques, some sequence homologies between Klebsiella pneumoniae and Klebsiella oitica and B27 were thought to be present, especially between these bacteria and the 66–74 region located within the B*2705 hypervariable region. Schwimmbeck et al. studied region 66–74 of B*2705 gene.70 71 They used computer searches to identify sequence homologies
between the B*2705 sequence and known sequences from bacteria. They found a homology of six consecutive amino acids (QTDRED) shared by B*2705 residues 72–77 located in the hypervariable region of the B27 molecule and Klebsiella pneumoniae nitrogenase 188–193. This is a hydrophilic sequence, and is thus predicted to be located at the outside of the protein possibly accessible to antibodies. Later, sequence similarities between B*2705 and proteins of other bacteria than Klebsiella were also identified. Table 3 shows the sequence similarities between some bacterial proteins and the various B27 subtypes.

Schwimmbeck et al\(^{70,71}\) raised antibodies in rabbits reacting both with peptides from B*2705 and peptides from Klebsiella pneumoniae nitrogenase. If the rabbits were immunised with B27 or Klebsiella nitrogenase synthetic peptides containing the homologous sequence, it was shown that affinity purified antibodies raised against either peptide also reacted with the other peptide. Although Tsuchiya et al\(^{67}\) found the same results, De Vries et al\(^{68}\) were not able to reproduce these findings.

Schwimmbeck et al\(^{70,71}\) also tested sera from AS and RS patients for reactivity against the peptide derived from Klebsiella pneumoniae nitrogenase 184–196, in sera from B27 positive male patients and B27 positive male controls, either from Norway or New Mexico was not different. The mean age of Norwegian patients and controls was 38 years ranging from 20 to 69, and 39 years ranging from 21 to 62, respectively. The mean age of the New Mexican patients and controls was 43 years ranging from 16 to 76, and 40 years ranging from 25 to 66 respectively. Although sera from some patients were reactive with the Klebsiella peptide, there was no positive correlation between a positive reaction with the Klebsiella nitrogenase peptide and a positive reaction with the B27 peptide 69–84. Cross inhibition studies were negative.

A very elegant study was carried out by Ewing et al\(^{77}\). Using overlapping peptides of eight residues from the B*2705 molecule, they found the frequency of antibodies against this peptide in sera from patients was higher than in sera from controls. This is in agreement with their finding that the frequency of antibodies against a B27 derived peptide containing residues 69–84 is increased.\(^{70,71}\) No cross inhibition studies were performed to study whether these antibodies were indeed crossreactive antibodies, and no age or sex matches were performed.

Tsuchiya et al\(^{67}\) found that the reactivity to Klebsiella nitrogenase peptide containing residues 184–196, in sera from B27 positive male patients and B27 positive male controls, either from Norway or New Mexico was not different. The mean age of Norwegian patients and controls was 38 years ranging from 20 to 69, and 39 years ranging from 21 to 62, respectively. The mean age of the New Mexican patients and controls was 43 years ranging from 16 to 76, and 40 years ranging from 25 to 66 respectively. Although sera from some patients were reactive with the Klebsiella peptide, there was no positive correlation between a positive reaction with the Klebsiella nitrogenase peptide and a positive reaction with the B27 peptide 69–84. Cross inhibition studies were negative.

As shown in table 4, they found that the frequency of antibodies against this peptide in sera from patients was higher than in sera from controls. This is in agreement with their finding that the frequency of antibodies against a B27 derived peptide containing residues 69–84 is increased.\(^{70,71}\) No cross inhibition studies were performed to study whether these antibodies were indeed crossreactive antibodies, and no age or sex matches were performed.

Tsuchiya et al\(^{67}\) found that the reactivity to Klebsiella nitrogenase peptide containing residues 184–196, in sera from B27 positive male patients and B27 positive male controls, either from Norway or New Mexico was not different. The mean age of Norwegian patients and controls was 38 years ranging from 20 to 69, and 39 years ranging from 21 to 62, respectively. The mean age of the New Mexican patients and controls was 43 years ranging from 16 to 76, and 40 years ranging from 25 to 66 respectively. Although sera from some patients were reactive with the Klebsiella peptide, there was no positive correlation between a positive reaction with the Klebsiella nitrogenase peptide and a positive reaction with the B27 peptide 69–84. Cross inhibition studies were negative.

A very elegant study was carried out by Ewing et al\(^{77}\). Using overlapping peptides of eight residues from the B*2705 molecule, they found the frequency of antibodies against this peptide in sera from patients was higher than in sera from controls. This is in agreement with their finding that the frequency of antibodies against a B27 derived peptide containing residues 69–84 is increased.\(^{70,71}\) No cross inhibition studies were performed to study whether these antibodies were indeed crossreactive antibodies, and no age or sex matches were performed.
showed that in fact the antibody response against the part of B*2705 containing the Klebsiella homologous sequence was not directed to the complete homologous 72-83 QTDRED sequence, but rather to flanking regions that included only a few of the homologous residues—that is, 68-KAKAQTD-75 and 76-REDLRTTL-83 of HLA-B27. Interestingly, they found that sera reacting with peptides derived from Klebsiella nitrogenase also did not recognise octapeptides containing the complete homologous sequence, but an epitope containing QTDR and residues to the left of this sequence that is not homologous to B*2705—that is, 185-NSRQTDR-191. Fifty B27 positive AS patient sera and sera from 22 B27 positive and 22 B27 negative first degree relatives were tested for reactivity to the 185-NSRQTDR-191 Klebsiella peptide with ELISA assays. In patient sera the binding as measured by the mean absorbance value in the ELISA was significantly (p<0.002) higher than in sera from the B27 negative control group, and also (but less significant, p<0.02) than in sera from the B27 positive control group. No age matches were performed. The overall conclusion by Ewing et al from their experiments was that sera from AS patients contained antibodies that reacted with overlapping epitopes of 5 to 8 amino acids within the sequence 183-ICNSRQTDR-191 on the Klebsiella nitrogenase molecule. Sera from AS patients showed a positive correlation between binding to the B27 peptide 68-KAKAQTD-75 and binding to the Klebsiella peptide 185-NSRQTDR-191. However, no cross inhibition studies, and studies with monoclonal or affinity purified antibodies were carried out, to show that antibodies were indeed crossreactive. Although QTDR seems to be an important sequence for activity with AS patient sera. Tsuchiya et al found that sera reacting with peptides derived from Klebsiella nitrogenase 184-CNSRQTDR-197. The experiments in which different peptides were used, showed that the ELISA used was specific for peptides containing certain amino acid residues. Lahesmaa et al, however, found that sera reacting with CNSRQTDRDEL containing the same amino acids but in which the crossreactive sequence was scrambled.

A computer search by Fielder et al revealed another sequence homology between a bacterial protein and HLA-B27. The PuD secretion protein of the starch inducible starch debranching enzyme pullulanase contains a sequence DRDE, which shows some similarity with DRED of B*2705. Peptides 67-CCKAKQTDREDLRTLTL-82 from B*2705 and 590-RPTVRQDREYQASS-605 from PuD were used as substrates to study the reactivity of patient and control sera. They found significantly increased antibody levels in sera from AS patients compared with controls or RA patients. No experiments were done to confirm the presence of crossreactive antibodies in positive sera. Patients and controls were not matched for HLA, sex or age. Control peptides from the scrambled PuD sequence were used to confirm sequence specificity of the tests. Tani et al found significantly increased titres of IgG and IgA against the PuD peptide in sera from active AS patients compared with sera from controls. No HLA, sex or age matches were performed, and controls were only 50% men compared with 90% men in the AS group. No differences were found in antibody levels against a control peptide, consisting of a scrambled sequence of the PuD peptide, between the different groups. However, the absorbance values obtained with the control peptides were much higher (±0.15) for all groups studied than those obtained with Klebsiella peptides and sera with negative (±0.15) and positive (±0.45) reactions.

Sequence similarities between B*2705 and proteins of other Gram negative bacteria than Klebsiella were also studied. It was found that Shigella flexneri strains that are isolated from ReA patients carry a plasmid (pHS-2). DNA sequence analyses of this plasmid revealed that it contains an open reading frame (ORF) encoding a 22 amino acid peptide with sequence homology to B27, again involving the sequence QTD—namely, GTVCQAT-DRHSLSIAMQ. Affinity purified rabbit antibodies against B*2705 showed a strong reactivity with the pHS-2 peptide. Of 15 affinity purified anti-B*2705 peptide antibodies from B27 positive patients only three recognised the Klebsiella nitrogenase 184–196 peptide, while 12 showed strong crossreactivity with the pHS-2 peptide. Affinity purified anti-B*2705 peptide antibodies from B27 positive patients only three recognised the Klebsiella nitrogenase 184–196, while 12 showed strong crossreactivity with the pHS-2 peptide. A higher proportion of AS patients compared with controls recognised the pHS-2 peptide and patients had increased titres against this peptide, although the differences were not significant.

The sera from the same Norwegian patients were used to study reactivity to a peptide from Yersinia enterocolitica, as Tsuchiya had identified sequence homology between B*2705 and the plasmid encoded Yersinia enterocolitica ORF 3 and Yersinia pseudotuberculosis, in contrast with Yop1 of the non-ReA associated Yersinia enterocolitica ORF 8. The 171-AIGDRSKTDRENSVSIGC-188 peptide used in the ELISA contained the homologous sequence Y op1 of the non-ReA associated Yersinia enterocolitica ORF 8. The 171-AIGDRSKTDRENSVSIGC-188 peptide used in the ELISA contained the homologous sequence Y op1 of the non-ReA associated Yersinia enterocolitica ORF 8. The 171-AIGDRSKTDRENSVSIGC-188 peptide used in the ELISA contained the homologous sequence Y op1 of the non-ReA associated Yersinia enterocolitica ORF 8.
Norwegian controls, especially IgA antibodies. However, anti-Yop1 antibody levels were not correlated with anti-B27 peptide antibody levels, although in one patient cross inhibition of the anti-Yop1 peptide antibodies with the B27 peptide was found. The mean age of the patients was 38 years, ranging from 20 to 69. Controls used were matched and had a mean age of 40 years, ranging from 21 to 62.

Another sequence homology exists between B*2705 and OMP-H of Salmonella typhimurium, again within the hypervariable region of B27. Lahesmaa et al tested for antibodies against the Yersinia enterocolitica O:3 Yop1, as well as for antibodies against the peptide from OMP-H containing the homologous sequence—that is, 50-QRLQSMKAGSDRTKLEKDV-68, in sera from AS, RS and ReA patients and healthy controls without performing HLA, sex or age matching. Thirty three per cent of AS patients and 42% of RS patients had antibodies against the Yop1 peptide, and 25% of AS patients and 40% of RS patients had antibodies against OMP-H. No data about healthy controls were included. The antibodies against Yop 1 were not directed against a part of the peptides with B27 homology, but to a flanking region left from this sequence. In this study it was also found that anti-Klebsiella pneumoniae nitrogenase antibodies were not directed against the B*2705 homologous sequence, but against a flanking region.

In 1992 a study from Lahesmaa was published in which 30 yersiniosis patients with ReA (one B27 negative, 30% female), 29 uncomplicated yersiniosis patients (all B27 negative, 34% female) and 79 controls with ReA (one B27 negative, 30% female), 29 published in which 30 yersiniosis patients with arthritis and those without arthritis. Experiments were also performed to determine more precisely the sequence specificity of the antibody reactivity. These showed that the antibodies were not directed against the tetrapeptide shared by Yop 1 and B27, but against a left flanking sequence of Yop 1. While proliferation against whole Yersinia lysates was present, no lymphocyte proliferation against the Yop 1 peptide was found when 15 yersiniosis patients (eight with ReA) and 16 healthy controls (50% B27 positive) were tested. None of the yersiniosis patients had IgG or IgA against the 184–197 Klebsiella nitrogenase peptide.

Conclusions
From the data available in the literature it can be concluded that there are no consistent results confirming the presence of increased autoreactivity in SpA patients compared with controls. When reviewing the literature on this subject, some problems are encountered.

The results reported by the different groups are obtained by various methods, different dilutions of sera are tested, and different antigen preparations have been used. In addition, another problem is the specificity of the ELISA assays used. Tsuchiya and Lahesmaa showed that experiments with appropriate control peptides should be carried out to confirm the sequence specificity of the ELISA assays used. De Vries et al clearly showed that a correction for non-specific binding of sera used in the ELISA assays is required. In none of the studies with positive findings, using sex and HLA matched controls, such corrections were done. The main problem, however, in determining the presence of autoreactivity in B27 associated SpA is that only in a few studies HLA, sex and age matched controls were included, as shown in table 1, table 2, and table 4.

The first studies showing an increased reactivity against B27 in the sera of AS and RS patients were done by Schwimmbeck et al. However, their findings could only be confirmed in those studies lacking both HLA and sex matched controls. Studies from groups using HLA and sex matches were not able to reproduce the results. Tsuchiya et al who found very high anti-B27 activity in some healthy B27 negative or even B27 positive women with previous pregnancies, illustrated the importance of using sex matches.

The above mentioned problems also apply for the studies determining the presence of antibodies crossreacting with B27 and bacterial proteins. It is clear that sequence similarities between HLA-B27 and some bacterial proteins exist, and that at least in rabbits antibodies reactive with both bacterial proteins and B27 can be raised. The relevance of this finding for the pathogenetic mechanisms in B27 associated SpA is not evident, and inconsistent data about the presence of these antibodies in patients are obtained. When the frequencies of the presence of antibodies against bacterial proteins and B27 in sera from AS and RS patients were compared with those in sera from healthy controls, the latter were almost never properly matched for age, while only three studies performed sex and HLA matches. Most studies did not perform any experiments to confirm the crossreactivity of antibodies. Tsuchiya and Lahesmaa clearly showed that experiments with appropriate control peptides should be carried out to determine the specificity of affinity purified antibodies.

Of the studies on crossreactive antibodies, in which controls were matched both for HLA-B27 and sex, one study found increased reactivity to Yersinia Yop 1 in patients. However, although in one patient cross inhibition of the anti-Yop 1 peptide antibodies with the B27 peptide was found, there was no correlation with anti-B27 peptide antibody levels. Another study produced negative results with Klebsiella nitrogenase. A positive correlation was found between recognition of B27 and...
pHS-2 peptides, and crossreaction of affinity purified anti-B27 antibodies with pHS-2 was observed in 13 of 15 patients who recognised B27. However, a statistically non-significant higher proportion of AS patients recognised the *Shigella* pHS-2 peptide.84

Some results suggest that in people with an anti-B27 response, the antibodies are not directed to parts of the B27 molecule showing sequence similarities with bacterial proteins, but rather to flanking regions.77 78 This is in agreement with findings that mice transgenic for HLA-B*2705 and human β2-microglobulin are tolerant to the B27 and bacterial crossreactive epitopes,79 and that peptides from regions that are non-homologous to self proteins are more readily recognised by the immune system than peptides from parts that are more homologous to self.85

The sequence similarities between B27 and the bacterial proteins nitrogenase, pullulanase, Yop1, pHS-2, and OMP-H, are located in a region of B27 where different B27 subtypes differ in one or more amino acids. The crossreactive sequences of the B27 molecule are completely identical in B27 subtypes associated with disease (B*2705 and B*2707) and a subtype that is probably not associated with disease (B*2709). The sequence similarities with bacterial proteins in B*2704 (which is associated with disease), and B*2706 (which is not associated with disease) are also identical, but differ both from B*2705 by a D to S substitution at residue 77. Schwimmbeck et al80 reported a strong influence of the sequence differences as found in parts of the various B27 subtypes containing the reported sequence similarities with bacterial proteins on anti-B27 antibody binding. They found that a single amino acid change of D to N (as found at residue 77 in B*2701 and B*2702) significantly reduced recognition by affinity purified antibodies raised against a B*2705 peptide, while a change of D to S (as found at residue 77 in B*2704, B*2706 and B*2708) completely abolishes this reactivity. This suggests that antibodies against these parts of the B27 molecule, containing the reported sequence similarities with the above mentioned bacterial proteins, are not likely to be involved in B27 associated disease.

HLA-B27 is not the only HLA molecule sharing sequence similarities with bacterial proteins.86 After the first studies had been published in which the role of molecular mimicry in B27 associated SpA was investigated, it has been suggested that the small chance that a sequence of 6 amino acids occurs in two different proteins, being only 1:64 000 000 (1:20sup3), supported the idea that molecular mimicry plays a part in the onset of B27 associated diseases.87 88 However, if a protein of x amino acids is screened for a perfect 6 amino acid match in a database of n amino acids the expected number of perfect matches is 0.05 sup(x)x sup(n) sup(x). Searching the SWISS-PROT database of 1996 that contained 1.5×10sup6 residues for a perfect six amino acid match with a 360 amino acid protein like B27, one would expect 0.05×1.5×10sup6×360=84 matches.89 Therefore, it is actually very possible to find 5, 6 and 7 amino acid matches between unrelated proteins, and indeed this is found for HLA-B27 as well as for other HLA-B alleles.16

Only very few experiments have been carried out to determine T cell reactivity against B27 in patients and controls. Interesting results have been obtained that suggest that the three dimensional structure of B27 can be modified by peptides or by homocysteine, thereby creating new conformational epitopes that are recognised by antibodies as well as T cells of some SpA patients.90 91 However, too few data are yet available about the presence of B27 specific, MHC class I or MHC class II restricted, T cell responses in patients and controls.

From this review it is concluded that there is no evidence that B27 associated diseases are autoimmune diseases as a consequence of autoimmune reactions. Although the B27 molecule shares some immunological determinants with bacterial constituents, there is no proof that these determinants are important for the pathogenesis of B27 associated SpA. Although some patients and healthy people produce antibodies to B27 and crossreactive antibodies to both B27 and bacterial proteins, there is no evidence that the frequency of increased titres of such antibodies in sera from patients is significantly higher than in sera from matched controls.

Funding: this study is published with support of the Edmond and Marianne Blauw Fund for Ophthalmology.

I would like to thank (in alphabetical order) the following persons for their contributions and for critically reading the manuscript: Dr L van Alphen, Laboratory of Vaccine Development and Immune Mechanisms, National Institute of Public Health and the Environment, Bithoven, the Netherlands; Prof dr J Dankert, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, the Netherlands; Prof dr T E W Felkamp, Arthron, Amsterdam, the Netherlands.

HLA-B27 associated spondyloarthropathy

15 Blauw I, van der Linden S, Nolhalmans L. An increased prevalence of anti-Borrelia burgdorferi antibodies in an- 

16 Scofield RH, Warren WL, Koelsch G, Harley JB. A hypoth- 
17 esis for the HLA-B27 immune dysregulation in spondyloarthropathy: contribution from enteric organ- 

17 Scortefici RH, Kuren B, Gross T, Warren WL, Harley JB. HLA-B27 binding of peptide from its own sequence and 
18 single-base-pair substitutions from bacteria implicated for spondyloar- 


19 Parham P. Presentation of HLA class I-derived peptides: 
20 potential involvement in allercroptosis and HLA-B27- 

20 Schimmigl P, Oldstone MB. Autoimmune pathogen- 


22 Kuberski TT, Morse HG, Rate RG, Bonnel MD. Increased 

23 Geczy AF, Geczy CS, Bashir HV, Edmonds JP. A factor(s) 
24 in Klebsiella culture filtrates specifically modifies an HLA- 
25 B27 cross-reactivity with peripheral blood mononuclear cells of patients with ankylosing spondylitis. Br J Rheumatol 1988; 27 (suppl) 2:58– 
26 60.

26 Baines M, Ehringer A, Avakian H, Samuel D, James DC. The 
27 use of enzyme immunocytochemical (EIA) and radiobinding 
28 assay to investigate the cross-reactivity of Klebsiella antigens and HLA B27 in ankylosing spondylitis patients and 

30 Georgopoulos K, Dick WC, Goodacre JA, Pain RH. A rein- 
31 minant(s) in ankylosing spondylitis. J Exp Med 1986; 164: 
32 759–72.

32 Geczy AF, Angenendt JK, Mcguigan LE, Uphold LL, Sul- 
33 livan JS. Cross-reactivity of anti-Klebsiella K43 B7: I sero- 

33 Seager K, Bashir HV, Geczy AF, Edmonds J, de Vere- 
34 weinbrenner AL. Evidence for a specific B27-associated cell sur- 
35 face marker on lymphocytes of patients with ankylosing 

34 MacSween RN, Dalakos TK, Jasani MK, Wilson ME, Boyle 
35 Vasey FB, Kinsella TD. Increased frequency of leukocyte- 
36 reactive antinuclear antibody in patients with ankylosing 


36 Blaauw I, van der Linden S, Nohlmans L. An increased 
37 potential involvement in allorecognition and HLA-B27- 

37 Georgopoulos K, Dick WC, Goodacre JA, Pain RH. A rein- 
38 minant(s) in ankylosing spondylitis (AS) are lytic for the mononuclear 
39 cells of AS patients. Br J Rheumatol 1988;27 (suppl) 2: 

40 Wang JY, Yeh HY, Tu ST, Chen AC. Immunological study 
41 of Shigella species. Evidence for molecular mimicry in the 
42 HLA-B27:13469–95.

41 Silverstein AM. A history of immunology. San Diego: 

42 Berendes A, Lernerv T, Avrameas S, Natural mouse IgG re- 
43 acts with self antigens including molecules involved in the 

43 Cohen IR, Cooke A. Natural autoantibodies might prevent 

44 Cohen IR, Cooke A. Natural autoantibodies might prevent 

45 Rose NR. The use of autoantibodies. In: Peter JB, Shoenfeld 
46 Y. eds. Autoantibodies. Amsterdam: Elsevier Science, 1996: 
47 xxvii-xxx.

47 Cohen IR, Cooke A. Natural autoantibodies might prevent 

48 Vasey FB, Kinnsda TD. Increased frequency of leukocyte- 
49 reactive antinuclear antibody in patients with ankylosing 

51 Tani Y, Sato H, Tanaka N, Kori K, Doida Y, Hukuda S. 

52 Vasey FB, Kinnsda TD. Increased frequency of leukocyte- 
53 reactive antinuclear antibody in patients with ankylosing 

53 Kinnsda TD, Miller J, Gofton JP, Vasey FB. Population 
54 studies of leukocyte-reactive antinuclear antibody and 

54 Tani Y, Sato H, Tanaka N, Kori K, Doida Y, Hukuda S. 

56 Fujita TT, Brown J, Dalec DG, Budapest SG, Rusah VN, Joshua 
57 T. Autoantibodies to human heat shock protein (Hsp)60 
58 may be induced by Escherichia coli proL. Clin Immunol 1996;103:329–35.

57 Juzula X, Mateo L, Dominguez P, Br. J. Contemers N, Nolla 
58 J. The prevalence of antiphospholipid antibodies in 

58 Vasey FB, Kinnsda TD. Increased frequency of leukocyte- 
59 reactive antinuclear antibody in patients with ankylosing 

60 Kinnsda TD, Miller J, Gofton JP, Vasey FB. Population 
61 studies of leukocyte-reactive antinuclear antibody and 

61 Tani Y, Sato H, Tanaka N, Kori K, Doida Y, Hukuda S. 

62 Vasey FB, Kinnsda TD. Increased frequency of leukocyte- 
63 reactive antinuclear antibody in patients with ankylosing 

63 Vasey FB, Kinnsda TD. Increased frequency of leukocyte- 
64 reactive antinuclear antibody in patients with ankylosing 

64 Vasey FB, Kinnsda TD. Increased frequency of leukocyte- 
65 reactive antinuclear antibody in patients with ankylosing 

65 Silverstein AM. A history of immunology. San Diego: 

66 Schwartz RS. Autoimmunity and autoimmune diseases. In: 

67 Vasey FB, Kinnsda TD. Increased frequency of leukocyte- 
68 reactive antinuclear antibody in patients with ankylosing 


HLA-B27 associated spondyloarthropathy, an autoimmune disease based on crossreactivity between bacteria and HLA-B27?
J H Ringrose

Ann Rheum Dis 1999 58: 598-610
doi: 10.1136/ard.58.10.598

Updated information and services can be found at:
http://ard.bmj.com/content/58/10/598

References
This article cites 100 articles, 25 of which you can access for free at:
http://ard.bmj.com/content/58/10/598#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Immunology (including allergy) (5144)
Genetics (968)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/